Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology
+$0.09 today
- Market cap
- $1.85B
- Beta
- 0.95
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$5.16
Volume 0.95M
Average 1.18M
VERA EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Vera Therapeutics, Inc.NASDAQ: VERA
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$107.49M, compared with -$74.54M a year earlier. Trailing-twelve-month EBITDA was -$393.82M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -101.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$107.49M+9.7% QoQ
- Last fiscal yearDec 2025
- -$291.62M-101.9% YoY
- LTMJun 2026
- -$393.82M-87.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -44.2% | +100.0% | +144.2 pp |
| 1 year | -101.9% | +100.0% | +201.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (291.62M) USD
- Year-over-year change
- -101.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (291.62M) | -101.9% |
| FY2024 | 2024-12-31 | (144.42M) | -56.7% |
| FY2023 | 2023-12-31 | (92.18M) | -3.7% |
| FY2022 | 2022-12-31 | (88.91M) | -174.3% |
| FY2021 | 2021-12-31 | (32.41M) | — |
EBITDA vs competitors
How VERA compares with its peers on the latest reported figures
- VERA's LTM Jun 2026 EBITDA of -$393.82M is the 8th highest of the 10 companies compared; the peer median is -$70.61M.
- Its year-over-year change of -87.1% is the lowest of 10, against a peer median of +24.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $58.49M | +176.6% | — | 25.2% | |
| LTM Jun 2026 | $43.43M | +163.2% | — | 9.4% | |
| LTM Mar 2026 | $39.48M | +82.4% | -1.9% | 10.7% | |
| LTM Jun 2026 | -$29.53M | +74.2% | — | 1550.9% | |
| LTM Mar 2026 | -$70.61M | -31.5% | — | 843.9% | |
| LTM Mar 2026 | -$153.62M | -5.2% | — | — | |
| LTM Mar 2026 | -$245.81M | -69.1% | — | — | |
| LTM Jun 2026 | -$393.82M | -87.1% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -$442.87M | -9.5% | — | 5986.3% |
| LTM Jun 2026 | -$574.94M | +24.1% | — | — | |
| Peer median (excluding VERA) | -$70.61M | +24.1% | -1.9% | 434.6% | |
Competitors are the stored peer set for VERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | (846K) | 0 | 0 | 0 |
| Gross Profit | 0 | 846K | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.48M | 69.84M | 78.23M | 126.17M | 215.26M |
| Selling, General & Admin | 11.92M | 21.91M | 23.79M | 41M | 100.22M |
| Operating Expenses | 34.4M | 91.75M | 102.01M | 167.17M | 315.47M |
| Depreciation & Amortization | 176K | (846K) | 21K | 105K | 468K |
| EBITDA | (32.41M) | (88.91M) | (92.18M) | (144.42M) | (291.62M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (34.4M) | (90.9M) | (102.01M) | (167.17M) | (315.47M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 15K | 1.75M | 7.98M | 20.71M | 24.48M |
| Interest Expense | 20K | 992K | 3.79M | 7.63M | 7.53M |
| Other Income / Expenses | 1.79M | 1.85M | 6.02M | 15.02M | 15.86M |
| Income Before Tax | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1K | 1K | 1K | 1K | 1K |
| Net Income | (32.61M) | (89.06M) | (95.99M) | (152.15M) | (299.62M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| EPS (Diluted) | (2.43) | (3.35) | (2.25) | (2.75) | (4.66) |
| Weighted Avg Shares | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
| Weighted Avg Shares (Diluted) | 13.44M | 26.57M | 42.71M | 55.33M | 64.23M |
Vera Therapeutics, Inc.
NASDAQ:VERA
Intrinsic Alpha fair value
Locked
Current Price
$25.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.